(Q34622654)

English

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

venous thromboembolism

1 reference

based on heuristic

inferred from title

author name string

T Fuji

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S Fujita

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S Tachibana

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Y Kawai

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2458-2468

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

New antithrombotics in the prevention of thromboembolic disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04021.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2010.04021.X

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34622654&oldid=1621755280"